Candidemia And Other Forms Of Invasive Candidiasis Therapeutics
1. Eraxis patent expiration
Treatment: Treatment of fungal infections
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5965525 | VICURON HOLDINGS | Cyclic peptide antifungal agents |
Feb, 2020
(5 years ago) | |
| US7709444 | VICURON HOLDINGS | Echinocandin pharmaceutical formulations containing micelle-forming surfactants |
Apr, 2021
(4 years ago) | |
| US6960564 | VICURON HOLDINGS | Echinocandin pharmaceutical formulations containing micelle-forming surfactants |
Apr, 2021
(4 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Sep 22, 2023 |
Drugs and Companies using ANIDULAFUNGIN ingredient
Market Authorisation Date: 17 February, 2006
Dosage: POWDER
More Information on Dosage
ERAXIS family patents
